Dados do Trabalho

Título

Dupilumab Improves Urticaria-Specific Quality of Life in Patients with Chronic Spontaneous Urticaria Uncontrolled by H1 Antihistamines

Resumo

Introduction
Chronic spontaneous urticaria (CSU) negatively impacts patients’ quality of life (QoL). The Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) captures physical, psychosocial, and practical domains of QoL in CSU patients. The current analysis evaluated the effect of dupilumab on CU-Q2oL items in omalizumab-naïve CSU patients inadequately controlled with H1 antihistamines.

Methods
This post-hoc analysis included data from 138 patients (dupilumab: 70, placebo: 68) of the LIBERTY-CSU CUPID Study A phase 3 trial (NCT04180488). The CU-Q2oL is a 23-item questionnaire scored on a 5-point Likert scale with scores ranging from 0─100; higher scores indicate greater impairment. Proportion of patients reporting the two worst (very much/extremely) and two best (not at all/a little) responses for each item was analyzed at baseline and Week-24, respectively.

Results
At baseline, the mean (SD) CU-Q2oL total score was 41.0 (17.3) and 46.7 (20.3) in the dupilumab and placebo arms, respectively. The top two “very much/extremely” bothered items were “itching” (dupilumab: 86%; placebo: 84%) and “hives” (dupilumab: 81%; placebo: 77%). At Week-24, a significantly greater proportion of dupilumab-treated patients reported “not at all/a little” bothered by itching (60%) and hives (69%) compared with placebo (37% and 37%, respectively). Significantly more dupilumab-treated patients reported “not at all/a little” impact across all 23 CU-Q2oL items versus placebo at Week-24 (all p<0.05).

Conclusion
In this 24-week study, dupilumab treated patients reported significant improvements across all CSU-related QoL domains (including itching and hives). Quality of life improvement with dupilumab addresses an important goal of urticaria treatment.